Calithera Biosciences (NASDAQ: CALA) Shares are trading low after the company announced that its CANTATA Telaglenastat study on Renal Cell Carcinoma has not achieved its primary objective. The company also announced a 35% reduction in the workforce.
Calithera Biosciences is a pharmaceutical company in the clinical stage. It focuses on the discovery and development of small molecule drugs directed against tumor targets and immune cells that control the main metabolic pathways in the tumor microenvironment.
Calithera Biosciences shares were trading down 42.77% to $ 2.81 at the time of publication. The stock had a 52 week high of $ 69.29 and a 52 week low of $ 43.63.
Bionano Genomics, Inc. (NASDAQ: BNGO) The shares were trading higher after the company published a study on genes at risk for autism.
Bionano Genomics is an instrumentation company for life sciences in the field of genome analysis. She is involved in the development and commercialization of the Saphyr system, a platform for detecting ultra-sensitive and ultra-specific structural variation that allows researchers and doctors to accelerate the search for new diagnoses and therapeutic targets and to streamline the study of changes in chromosomes.
Bionano Genomics shares were trading up 96.92% to $ 6.06. The stock has a 52-week high of $ 7.11 and a 52-week low of 25 cents.
Ocugen (NASDAQ: OCGN) Shares are trading higher after its partner Bharat Biotech received a USA for its Covid-19 Covaxain in India. The company has rights to Covaxin in the United States.
Ocugen is a clinical biopharmaceutical company. It is focused on the discovery, development and commercialization of a line of innovative therapies that treat rare and poorly served eye diseases.
Ocugen’s shares were trading up 74.20% to $ 3.19. The stock has a 52-week high of $ 3.50 and a 52-week low of 17 cents.
Tiziana Life Sciences (NASDAQ: TLSA) Shares are trading higher after the company announced the completion of a clinical trial with its monoclonal anti-CD3 antibody for the treatment of COVID-19 patients in Brazil.
Tiziana Life Sciences is involved in the business of developing new cancer therapies with a focus on advanced stage growth and complementary diagnostic tools, with the ability to predict the aggressiveness of the disease and the prognosis in patients with breast cancer.
Tiziana Life Sciences shares were trading up 22.28% to $ 2.47. The stock has a 52-week high of $ 12.17 and a 52-week low of 62 cents.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.